A total of 237 venture capital (VC) funding deals worth $2.9 billion were announced in China during January 2023, which is a decline of 31.7% in terms of deals volume and 32.9% by value compared to the previous month. The corresponding year-on-year (YoY) deal value is more than halved by a massive 62.4%, reveals GlobalData, a leading data and analytics company.

An analysis of GlobalData’s Financial Deals Database reveals that the VC funding deals volume registered a YoY decline of 36.5% during the month.

Aurojyoti Bose, Lead Analyst at GlobalData, comments: “China is a key market for VC funding activity in the Asia-Pacific (APAC) region and this decline is in line with the global trend. Other key global markets such as the US and the UK also experienced MoM as well as YoY decline in VC funding activity.”

China is also a key global market for VC funding activity and ranks just next to the US in terms of deal volume as well as value. China accounted for 16.8% share of the total number of VC funding deals announced globally in January 2023 while its share in terms of value stood as 20.6%.

Some of the notable VC funding deals announced in China during January 2023 include $295.1 million funding raised by Anhui Huasun Energy, $218 million funding raised by BioRay Pharma, $177 million worth of funding raised by Yuze Semiconductor and $107 million funding raised by HighTide Therapeutics, among others.

Note: Historic data may change in case some deals get added to previous months because of a delay in disclosure of information in the public domain.